Indeed, the Geldanamycin (GA) analog 17-AAG combined with TZ and TZ-TDM1 showed clinical efficacy in ERBB2+ breast cancers reporting tumor progression when treated with TZ alone [14–18], suggesting that it may represent an effective strategy to overcome, or prevent drug resistance. Here, ERBB2 is linked to neoplasm.